# To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

Source: https://onco.cc/trials/nct06194448/  
OnCo record `nct06194448` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Osimertinib, Carboplatin, Cisplatin and Pemetrexed in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.

## Summary

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations is a phase 2 interventional study registered as NCT06194448 by AstraZeneca, with 76 participants enrolled, started 2024-04-21 and due to reach its primary completion in 2026-07-07. Interventions recorded: Osimertinib, Cisplatin or Carboplatin; Pemetrexed or Paclitaxel and Radiation.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06194448
- Phase: 2
- Setting: A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA)
- Sponsor: AstraZeneca
- Enrolled: 76

## Sources

- ClinicalTrials.gov NCT06194448: https://clinicaltrials.gov/study/NCT06194448

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06194448.json